Le Lézard
Classified in: Health
Subject: PER

Intravacc announces formation of Scientific Advisory Board


BILTHOVEN, the Netherlands, Feb. 23, 2021 /PRNewswire/ -- Intravacc, a world leader in translational research and development of vaccines, today announced the formation of a Scientific Advisory Board ("SAB"), chaired by Intravacc's Chief Scientific Officer Virgil Schijns and further comprising scientific leaders in the fields of vaccinology, infectious diseases and oncology. Intravacc's SAB will be consulted to help define the proper vaccine strategies and solutions to establish an impact on public health supported by convincing scientific clinical data. The SAB will also advise on the company's research strategy and approaches to optimize therapy effectiveness and added value.

Intravacc B.V. logo

Prof. Dr. Virgil Schijns, Intravacc's Chief Scientific Officer, commented:

"We are delighted to launch our Vaccine Scientific Advisory Board with these impressive scientists as charter members. We view their agreement to advise us on the development of our groundbreaking multiplatform vaccines as a vote of confidence in our technology. This distinguished group of scientific leaders can provide Intravacc with highly valued counsel and guidance as we continue expanding our contract development and manufacturing franchise, including our pioneering endeavors in therapeutic vaccines". 

Prof. Dr. Evelien Smits is research professor in tumor immunology and cancer immunotherapy at the University of Antwerp, Belgium. She is researching how the immune system of cancer patients can be provided with the necessary weapons to win the battle against cancer cells.

Dr. Harry Flore is Chairman of the Supervisory Board of HAL Allergy Holding of Leiden, the Netherlands - one of Europe's top players in the field of allergen immunotherapy, and a world leader in the production of modified allergen extracts for both therapeutic and diagnostic purposes. He is also active in HALIX, a CDMO, specializing in cell culture-based pharmaceutical production.

Prof. Dr. Anke Huckriede is Professor of Vaccinology at the University of Groningen, the Netherlands, and is affiliated with the University Medical Center Groningen. Huckriede's research activities are aimed at vaccine development, with a focus on rational vaccine design. Her work on (influenza) vaccines focuses, among other things, on developing in vitro techniques for vaccine evaluation and understanding the effects of pre-existing immunity on responses to vaccination.

Dr. Paul Wichgers Schreur is a senior scientist in the field of arbovirology at Wageningen Bioveterinary Research (WBVR). Using techniques like reverse-genetics, single-molecule microscopy, and bacterial superglue he studies the infection cycle of bunyaviruses and uses this knowledge to (co)develop therapeutic antibodies and vaccines.

Dr. Marien de Jonge is Associate Professor at Radboud University Medical Center, acting as Head of the Pediatric Infectious Diseases Section. He has more than 15 years of experience in both academic research and industrial R&D, mainly in the field of vaccine development and infectious diseases.

Dr. Paul Oostvogel M.D. is medical microbiologist. He has been involved in the Polio Eradication Initiative from the start in 1989. He retired in 2019 as head of the Public Health Laboratory of the Public Health Service (GGD) Amsterdam.

Dr. Jan Groen, Intravacc's CEO, said:

"I am delighted to have such an accomplished and diverse group of scientific, clinical and industry experts as inaugural members of our Scientific Advisory Board. Their expertise will ensure our activities remain firmly based on sound science and will help us discover new opportunities for vaccine innovation.''

About Intravacc

Dutch Intravacc, located at Utrecht Science Park Bilthoven, is a leading global contract developer and producer of innovative vaccines against infectious diseases. As an established independent CDMO organization with over 100 years of experience in the development and optimization of vaccines and vaccine technologies, Intravacc has transferred its technology related to polio vaccines, measles vaccines, DPT vaccines, Hib vaccines and influenza vaccines around the world. Around 40% of childhood disease vaccines are based on Intravacc's technology. Intravacc offers a wide range of expertise for independent vaccine development, from concept to Phase I/II clinical studies for partners around the world, including universities, public health organizations (WHO, Bill & Melinda Gates Foundation), biotech and pharmaceutical companies.

For more information, visit www.intravacc.nl

Contacts:

Intravacc
Dr. Jan Groen, CEO
P: +31 30 7920 454

Mirjam Hartman, Media relations
P: +31 6 115 969 94
E: [email protected]

LifeSpring Life Sciences Communication, Amsterdam
Leon Melens
P: +31 6 538 16427
E: [email protected]  

Logo - https://mma.prnewswire.com/media/1334670/Intravacc_Logo.jpg


These press releases may also interest you

11 aoû 2022
NorthWest Healthcare Properties Real Estate Investment Trust (the "REIT") , today announced its results for the three and six months ended June 30, 2022. NorthWest's inflation indexed $10.2 billion, 232 property portfolio performed well in the second...

11 aoû 2022
Daiichi Sankyo (TSE: 4568) and AstraZeneca's (LSE/STO/Nasdaq: AZN) ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been approved in the U.S. for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose...

11 aoû 2022
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (FRA: JAM1), a leader in cannabinoid-based drug discovery and development, announced today that it has entered into a subscription agreement (the "Subscription Agreement") with Global Corporate...

11 aoû 2022
J INTS BIO announced that the pre-clinical data of its novel, orally administered 4th generation EGFR TKI 'JIN-A02' was presented at the 2022 IASLC World Conference on Lung Cancer in Vienna, Austria on 8th August, at the official session "Overcoming...

11 aoû 2022
The interspinous spacers market size was valued at US$ 70.94 Mn in 2021. The global market is...

11 aoû 2022
WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, today announced a licensing agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson ("Janssen"). Under this agreement, WuXi...



News published on 23 february 2021 at 02:00 and distributed by: